Moreover, our observations that mycolactone efficiently kills tumors from treatment naive and relapsed MM patients ex vivo and delays MM xenograft growth in a pre‐clinical murine model of disease establish Sec61 as a novel therapeutic vulnerability in MM. This evidence concerns the gene SEC61A1 and Miyoshi myopathy.